UPDATE ON INVESTMENT PORTFOLIO

18 March 2026

BIOPHARMA CREDIT PLC

(THE "COMPANY")

UPDATE ON INVESTMENT PORTFOLIO

New Investment of US$50 Million and Paratek Repayment

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investment trust, notes the announcement released by Paratek Pharmaceuticals, Inc. ("Paratek") on 18 March 2026 regarding the completion of its combination with Radius Health, Inc. (the "Transaction"). 

Paratek - New US$50 Million Investment

As noted by Paratek, the Transaction was financed in part with debt financing from funds managed by Blackstone; Sixth Street; Oaktree Capital Management, L.P.; Silver Point Capital; and Pharmakon Advisors, LP (the "New Paratek Financing"). The Company is pleased to announce that it, through its fully owned subsidiary, and BioPharma Credit Investments V (Master) LP ("BioPharma-V"), each funded US$50 million in the New Paratek Financing. The Company's new investment as part of the Transaction replaced a previous debt financing in which the Company had a US$25 million investment, which was repaid in its entirety by the New Paratek Financing. Since Paratek is a privately held company, further details about the New Debt Financing are not publicly available, but the terms of the loan are generally comparable with the Company's other investments.

Paratek is a privately held specialty pharmaceutical platform company with a portfolio of diverse, innovative medicines well positioned for long-term growth. Paratek's product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic indicated for adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). In connection with the Transaction, Paratek added the osteoporosis therapy TYMLOS (abaloparatide) to its growing commercial portfolio of differentiated specialty medicines. Paratek became a private company in 2023 when it was acquired by B-FLEXION Life Sciences and Novo Holdings. The Transaction brings together two complementary organizations backed by B‑FLEXION Life Sciences, and further advances Paratek's growth strategy of building a pharmaceutical platform in high-need, targeted therapeutic areas. The combined company is expected to generate nearly $1 billion in revenue in 2026, reflecting the scale and breadth of Paratek's platform.

Paratek - Prepayment

In connection with the closing of the New Paratek Financing, the previous US$275 million senior secured facility at Paratek was repaid in full. The Company had previously announced on 22 May 2025 the entering into of the US$275 million senior secured facility, of which each of the Company and BioPharma-V funded US$25 million at closing. The Company received a payment of US$27 million, comprised of US$25 million in returned principal and US$2 million of prepayment fees and accrued interest.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

[email protected]

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.